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Abstract
Background: The FRAX® tool estimates the risk of a fragility fracture among the population and many countries
have been evaluating its performance among their populations since its creation in 2007.
The purpose of this study is to update the first FRIDEX cohort analysis comparing FRAX with the bone mineral
density (BMD) model, and its predictive abilities.
Methods: The discriminatory ability of the FRAX was assessed using the ‘area under curve’ of the receiver operating
characteristic (AUC-ROC). Predictive ability was assessed by comparing estimated risk fractures with incidence
fractures after a 10-year follow up period.
Results: One thousand three hundred eight women ≥ 40 and ≤ 90 years followed up during a 10-year period. The
AUC for major osteoporotic fractures using FRAX without DXA was 0.686 (95 % CI 0.630–0.742) and using FN
T-score of DXA 0.714 (95 % CI 0.661–0.767). Using only the traditional parameters of DXA (FN T-score), the AUC was
0.706 (95 % CI 0.652–0.760). The AUC for hip osteoporotic fracture was 0.883 (95 % CI 0.827–0.938), 0.857 (95 % CI 0.
773–0.941), and 0.814 (95 % CI 0.712–0.916) respectively. For major osteoporotic fractures, the overall predictive
value using the ratio Observed fractures/Expected fractures calculated with FRAX without T-score of DXA was 2.29
and for hip fractures 2.28 and with the inclusion of the T-score 2.01 and 1.83 respectively. However, for hip fracture
in women < 65 years was 1.53 and 1.24 respectively.
Conclusions: The FRAX tool has been found to show a good discriminatory capacity for detecting women at high
risk of fragility fracture, and is better for hip fracture than major fracture. The test of sensibility shows that it is, at
least, not inferior than when using BMD model alone. The predictive capacity of FRAX tool needs some adjustment.
This capacity is better for hip fracture prediction and better for women < 65 years. Further studies in Catalonia and
other regions of Spain are needed to fine tune the FRAX tool’s predictive capability.
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Background
Osteoporosis is of particular public health interest due
to its association with subsequent fractures and the well-
documented risk of mortality and disability leading to an
increase in medical care costs in many regions of the
world as a result [1, 2].
Over the last decade the attitude towards osteoporotic
fracture risk evaluation has changed because an increase
in information about using various clinical risk factors
(CRFs) and not only the values of bone mineral density
(BMD) [3]. To provide risk assessment, especially for
those professionals who are less familiarized with the ap-
proach to this health problem, several prediction models
have been developed to be used in clinical practice.
There are three instruments that have been commonly
used in recent times that help to identify people at a
high risk of osteoporotic fracture over a period of time:
the FRAX® (Fracture Risk Assessment tool) [4], the
QFractureScores [5] and the Garvan Fracture Risk
Calculator [6, 7].
FRAX instrument was launched by WHO in 2008, and
gives the absolute risk of fragility fracture as a percent-
age during a 10-year period. The risk estimate is carried
out by a calculator available online by putting in the
value of clinical variables that have shown a strong asso-
ciation with osteoporosis and fracture across different
studies and systematic reviews [8–14]. The calculator is
able to recalculate the risk with the inclusion of Dual-
energy X-ray absorptiometry (DXA) parameters. Epi-
demiological osteoporotic fracture data in four areas has
been used in its construction (clinical spine, distal fore-
arm, hip or proximal humerus), as well as the mortality
data available from different continents. Once the tool
has been accessed online, it is necessary to select the
relevant study population. During the last few years,
there have been several studies focused on evaluating
how FRAX behaves among different populations other
than the one in which the model was developed. System-
atic reviews identify studies that assess the FRAX tool
ability to discriminate between individuals who are at
risk of fracture and those who are not. Also, its predict-
ive ability to identify people at high risk of future frac-
tures, fracture risk thresholds and identifying which risk
thresholds are cost-effective when it comes to carrying
out a therapeutic intervention. It is still to be determined
whether the CRFs are of significance on the outcome of
fracture data in different cohorts [15–24].
In Spain, FRAX performance has been assessed during
its use in different cohorts since 2008 and it has shown
a good discriminative capacity, but a tendency to under-
estimate major osteoporotic fractures has been observed
[25–27]. However, the underestimation was lower in
cases of hip osteoporotic fractures. This does not detract
from the strengths of the tool for clinical use in
decision-making as long as their possible limitations are
taken into account.
This study aims to expand the sample before FRIDEX
cohort [25] to test the FRAX algorithm against the re-
sults of reliability of BMD in its discriminative and pre-
dictive ability for predicting absolute risk of fracture in
10 years. This is to provide more evidence for clinicians
about how well the tool performs among the Spanish
population.
Methods
The FRIDEX cohort features have previously been pub-
lished [28]. At the beginning of the study, the partici-
pants underwent axial bone densitometry DXA after
accepting by informed consent to answer a question-
naire on risk factors (QRF) for osteoporotic fracture
and further contact. Self-reported incident fractures
10 years later were assessed using a telephone question-
naire (TQ).
Eligibility criteria
Patient inclusion criteria
Randomized sample (simple computerized randomization
stratified) was obtained from Caucasian women ≥ 40
and ≤ 90 years of age at the time of inclusion in the
FRIDEX cohort, who understood and spoke the Spanish
language, and were able to respond to the initial QRF
and a 10-year follow up TQ. None of these patients had
been treated with antiosteoporotic medication (AOM)
prior to the study. Some of these patients, however,
may have been treated with AOM during the 10-year
study period.
Patient exclusion criteria
Patients who refused informed consent to participate in
the study and those without a telephone contact number
or did not respond after 3 phone calls made at different
times according to the procedure manual. Patients with
physical or psychological difficulties that prevented their
participation in the study with or whose relatives refused
them permission to participate. Subjects with Paget’s dis-
ease or bone cancer were also excluded.
Data collection
The baseline QRF variables were collected from 2000
to 2010 along with DXA, and they included patient
demographic (date of birth, sex) and anthropometric
characteristics (weight, height, body mass index (BMI)).
During the same visit, clinical risk factors for fracture
including QRF were recorded as well: family history of
hip fracture (father/mother), medical history of fragility
fracture, smoking, alcohol risk intake, history of gluco-
corticoids intake and medical history of antiosteoporo-
tic medication.
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Analysis carried out by using a Lunar GE model
Prodigy Advance densitometer with 11.4 software and
with BMD and T-score determination with NHANES III
references. DXA criteria were determined according
to the recommendations made by the International
Society for Clinical Densitometry (ISCD) in 2007 (http://
www.iscd.org/official-positions/). The densitometry diag-
nostic criteria of osteoporosis used were the 1994
WHO criteria (T-score ≤ −2.5 standard deviation of the
average mean value for young women at the femoral
neck (FN)) [29].
After a 10-year follow up period (2000–2010) variables
regarding new self-reported fragility fractures occurring
from the time of inclusion and number of falls over the last
year were collected. The major osteoporotic fractures (hip,
humerus, forearm and clinical spine) during the follow up
period were taken as the endpoint event. In all cases of
fracture, medical records were contrasted and those cases
of self-reported fractures that were impossible to confirm
with medical records were also excluded from analysis.
The estimated absolute risk of sustaining a major
osteoporotic fracture or hip fracture during the 10-year
period according to the FRAX-Spain tool (both with and
without baseline FN T-score) was determined through
the official website (version 3.2 accessed on October
2010) and analysed by two blinded investigators.
Statistical analysis
The characteristics of the population were described ac-
cording to descriptive univariate analysis. We used the
Chi-square test to evaluate the association between
qualitative variables. The Student’s t-test or, if necessary,
its nonparametric equivalent, the Mann-Whitney U test,
was implemented to evaluate the differences in the dis-
tribution of a quantitative variable according to the cat-
egories defined by a binary exposure. To assess the
differences in the distribution of a quantitative variable
according to the categories defined by a categorical vari-
able with more than two categories, ANOVA analysis of
variance or its corresponding non parametric test (Kruskal-
Wallis) were used.
The discriminating ability of the FRAX tool to identify
people at increased risk of fracture after a 10-year period
was assessed using the area under the curve (AUC) of
receiver operating characteristic (ROC) curves and the
Hosmer-Lemeshow goodness-of-fit test.
The calibration was assessed by comparing estimated
risk of fracture with observed fracture incidence.
All the statistical tests were undertaken with a confi-
dence interval of 95 % and with the use of the 17th ver-
sion of the SPSS statistical package.
This work follows the STROBE initiative for cohort stud-
ies’ guidelines [http://www.strobe-statement.org/index.ph
p?id=strobe-publications WebCite].
Results
Three thousand three hundred ninety-seven cohort pa-
tients were 2:1 randomly selected among patients who
had completed the 10-year period. A total of 1918
women were contacted at the end of the 10-year period
and in 1479 cases was impossible to contact by tele-
phone: 490 (14.4 %) unknown telephone or postal ad-
dress, 792 failed to respond to 3 calls (23.3 %), and 197
deaths (5.8 %). Out of 86 subjects that refused to partici-
pate (4.5 %), 33 were excluded due to cancer (1.8 %) and
491 because they had been receiving AOM at baseline
(25.6 %). This left a total of 1308 participants that ful-
filled the inclusion criteria and provided informed con-
sent to participate in the study.
Table 1 shows the distribution of the baseline charac-
teristics in the individuals selected and those selected,
but did not participate in the study. Overall, no signifi-
cant differences were observed between these two
groups. The only significant differences were found
among participants with a 2 year age differences (57.5
vs. 59.3 years), that had had fewer previous fractures
(22.6 vs 26.0 %), were taking less glucocorticoids (4.7 vs.
6.5 %) and had less osteoporosis according to baseline
DXA scan (32.7 vs 37.3 %).
We examined the frequency of fragility fractures during
the 10-year study period: a total of 153 fractures were reg-
istered, 133 of which corresponded to any of the four
areas of FRAX major osteoporotic fractures: hip, humerus,
forearm or clinical spine. 108 women reported a total of
133 major osteoporotic fractures which were contrasted:
26 women with 27 hip fractures, 26 with 33 proximal hu-
merus fractures, 40 with 56 distal radius fractures, and 16
with 20 clinical vertebral fractures (Table 2).
A summary of the main participants’ characteristics
can be seen in Tables 3 and 4 (with their relative risks
[RR]). Every risk factor is shown and categorized as
major or hip fracture respectively. Risk factors in-
cluded in the FRAX tool were also taken into consid-
eration, along with the variable of falls during the
previous year. The BMD measurement computed by
WHO international reference standard for description
of osteoporosis as a T-score ≤ −2.5 standard deviation
(SD) and osteopenia as a T-score between −1.0 and
−2.5 SD was also taken into account. The CRFs values
across both major and hip fractures show significant
differences in age, previous fractures and due to the
existence of DXA osteoporosis diagnosis. Table 3
shows in the analysis of major osteoporotic fracture
significant differences in patients with fractures
related to low BMI and in patients without fractures
related to normal baseline DXA. Table 4 shows signifi-
cant differences among patients with rheumatoid arth-
ritis and taking corticoids in the hip osteoporotic
fracture group.
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The mean of FRAX risk for major fracture among
women with fracture was 6.44 (6.94 SD) without FN T-
score and 8.25 (9.19 SD) with FN T-score, and for hip
fracture it was 2.38 (5.20 SD) and 3.59 (7.39 SD), re-
spectively. The mean for major fracture among without
fracture women was 3.35 (2.81 SD) without FN T-score
and 3.73 (3.48 SD) with FN T-score, and for hip fracture
it was 0.74 (1.40 SD) and 0.86 (1.94 SD), respectively. All
measurements show significant differences (p < 0.001)
between women with fracture and without fracture.
The AUC ROC analysis was carried out to compare
fracture discrimination on the basis of three different
scenarios for major and hip fractures: guidance on the
basis of BMD testing alone in decision-making (FN T-
score), FRAX tool calculated without BMD, and FRAX
with FN T-score. For major fracture the best-case sce-
nario was obtained with FRAX tool including FN T-
score [AUC = 0.714, 95 % CI 0.661–0.767], followed by
FN BMD alone [AUC= 0.706, 95 % CI 0.652–0.760] and
FRAX tool without BMD [AUC= 0.686, 95 % CI 0.630–
0.742]. For hip fracture the best-case performance analysis
was obtained with FRAX without BMD [AUC = 0.883,
95 % CI 0.827–0.938], followed by FRAX including FN T-
score [AUC= 0.857, 95 % CI 0.773–0.941] and FN BMD
alone [AUC= 0.814, 95 % CI 0.712–0.916]. In all cases,
the results showed significant differences (p < 0.001) with
the reference value [AUC= 0.50].
The adjusted predictive capacity of FRAX analysed
using the mean ratio between observed fractures
(ObsFx) during the 10-year follow-up period of the co-
hort and the fracture risk estimates rates (ExpFx) was
2.29, CI 95 % 1.91–2.74) for major osteoporotic fracture
and 2.28 [CI 95 % 1.56–3.32] for hip fracture using the
FRAX tool without BMD, and on the introduction of the
FN T-score was 2.01 [CI 95 % 1.68–2.41] and 1.83 [CI
95 % 1.25–2.67], respectively (Table 5). This ratio
remained similar when we categorized the results based
on age, except among women younger than 65 years of
Table 1 FRIDEX cohort (Contacted/Non-Contacted)
Contacted Non-Contacted p-value 95 % CI
1918 (56.5 %) 1479 (43.5 %)
Age (SD) 57.5 (8.1) 59.3 (9.9) 0.001 [1.1–2.4]
BMI Kg/cm2 (SD) 27.7 (4.6) 27.5 (4.5) 0.506 ns
BMI < 20 Kg/cm2 (%) 2.4 2.6 0.723 ns
Personal history of fractures (%) 22.6 26.0 0.014 [0.5–6.3]
Parental Hip Fracture (%) 22.7 21.1 0.335 ns
Current Smoking (%) 10.8 10.8 0.802 ns
High alcohol intake (%) 0.7 0.9 0.667 ns
Glucocorticoids (%) 4.7 6.5 0.022 [0.2–3.4]
Rheumatoid arthritis (%) 1.3 1.8 0.158 ns
Ca + vitamin D supplements (%) 22.2 22.2 0.916 ns
Osteoporosis in DXA (%) 32.7 37.3 0.012 [1.4–7.8]
CI confidence interval, SD standard deviation, BMI body mass index, ns non statistical significance, DXA dual-energy X-ray absorptiometry
Table 2 All fractures at 10 year follow up in two groups of age
<65 years ≥65 years Total p-value 95 % CI
n = 1056 (80.7 %) n = 252 (19.3 %) n = 1308
Age (SD) 54.1 (5.3) 70.3 (4.4) 57.2 (8.2) <0.001 [15.6–16.9]
Women/Fractures Women/Fractures Women/Fractures
All fractures 101/129 (9.6 %) 52/74 (20.6 %) 153/203 (11.7 %) <0.001 [5.7–16.3]
Major fracturesa 65/78 (6.2 %) 43/55 (17.1 %) 108/133 (8.3 %) <0.001 [6.0–16.8]
Hip 6/6 (0.6 %) 20/21 (7.9 %) 26/27 (2.0 %) <0.001 [3.9–10.7]
Vertebral 10/13 (1.0 %) 6/7 (2.8 %) 16/20 (1.4 %) 0.026 [0.3–3.9]
Humerus 21/24 (2.3 %) 5/9 (3.2 %) 26/33 (2.4 %) 0.409 ns
Wrist 28/35 (2.9 %) 12/18 (6.0 %) 40/56 (3.5 %) 0.016 [0.2–6.2]
CI confidence interval, SD standard deviation, ns non statistical significance
aMajor osteoporotic fractures (hip, vertebra, humerus, wrist)
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age in which case the FRAX without/with BMD result
dropped in the hip fracture category to 1.53 [CI 95 %
0.70–3.32] and 1.24 [CI 95 % 0.57–2.68], respectively.
The Hosmer-Lemeshow test was carried out in order
to assess the ‘goodness of fit’ obtained by grouping data
according to quintiles of results of fracture (Fig. 1). First
of all it shows the observed and predicted values of the
sample within major fracture and hip fracture for the re-
sults of the FRAX tool without BMD and with the FN
BMD T-score. It then shows the same results after
multiplication (simulation) by approximately the number
of times that the ObsFx is greater than the ExpFx.
Table 3 Baseline fracture risk factors between patients for ‘major osteoporotic fracture’
With Fracture
(n = 108)
Without Fracture
(n = 1200)
p- value 95 % CI RR RR 95 % CI
Age (SD) 61.6 (9.4) 56.8 (8.0) <0.001 [2.9–6.6]
Age > 65 years (%) 39.8 17.4 <0.001 [12.9–31.9] 2.77 a [1.9–4.0]
BMI (SD) 27.6 (4.6) 28.0 (4.7) 0.518 ns - -
BMI < 20 (%) 5.6 2.3 0.036 [1.1–7.7] 2.27 b [1.1–4.4]
Previous fracture (%) 42.6 19.5 <0.001 [13.5–32.7] 2.72 [1.9–3.9]
Parental hip fracture (%) 15.7 14.1 0.637 ns 1.13 [0.7–1.8]
Smoker (%) 9.3 11.7 0.452 ns 0.79 [0.4–1.4]
Alcohol risk (%) 0.9 0.7 0.541 ns 1.35 [0.2–5.4]
Corticoids (%) 8.3 4.7 0.093 ns 1.74 [0.9–3.2]
Rheumatoid arthritis (%) 2.8 1.0 0.120 ns 2.46 [0.9–5.7]
Falls previous year (%) 34.3 22.3 0.005 [2.7–21.3] 1.71 [1.2–2.5]
Osteoporosis (baseline DXA) (%) 51.9 26.1 <0.001 [16.1–33.6] 6.07 c [2.9–12.9]
Osteopenia (baseline DXA) (%) 41.7 49.9 0.103 ns 2.95 d [1.4–6.4]
Normal (baseline DXA) (%) 6.5 24.0 <0.001 [12.3–22.7] - -
CI confidence interval, RR relative risk, SD standard deviation, BMI body mass index, ns non statistical significance, DXA dual-energy X-ray absorptiometry
a < 65 vs ≥ 65 years
b < 20 vs ≥ 20
c Osteoporosis vs normal
d Osteopenia vs normal
Table 4 Baseline fracture risk factors between patients for ‘hip osteoporotic fracture’
With fracture (n = 26) Without fracture (n = 1282) p- value 95 % CI RR RR 95 % CI
Age (SD) 69.7 (6.8) 56.9 (8.0) <0.001 [9.7–15.9] - -
Age > 65 (%) 76.9 18.1 <0.001 [42.5–75.1] 13.97 a [5.8–33.5]
BMI (SD) 27.2 (3.5) 27.9 (4.8) 0.310 ns
BMI < 20 (%) 3.8 2.5 0.664 ns 1.55 b [0.3–8.2]
Previous fracture (%) 53.8 20.7 <0.001 [13.8–52.4] 4.28 [2.0–9.0]
Parental hip fracture (%) 19.2 14.1 0.460 ns 1.44 [0.6–3.6]
Smoker (%) 0 11.7 0.063 ns - -
Alcohol risk (%) 0 0.7 0.834 ns - -
Corticoids (%) 15.4 4.8 0.036 [3.3–24.5] 3.48 [1.3–9.2]
Rheumatoid arthritis (%) 7.7 1.0 0.034 [3.6–17.0] 7.18 [1.9–22.3]
Falls previous year (%) 38.5 23.0 0.065 ns 2.06 [1.0–4.4]
Osteoporosis (baseline DXA) (%) 65.4 27.5 <0.001 [19.4–56.3] 6.80 c [1.8–26.3]
Osteopenia (baseline DXA) (%) 26.9 49.7 0.021 [5.5–40.1] 1.60 d [0.4–6.8]
Normal (baseline DXA) (%) 7.7 22.9 0.067 ns - -
CI confidence interval, RR relative risk, SD standard deviation, BMI body mass index, ns non statistical significance, DXA dual-energy X-ray absorptiometry
a < 65 vs ≥ 65 years
b < 20 vs ≥ 20
c Osteoporosis vs normal
d Osteopenia vs normal
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Discussion
The FRAX tool has been analysed in this study to meas-
ure its discriminative capacity as a model for the predic-
tion of osteoporotic fracture compared with the BMD
model, as well as its predictive capacity and the ‘good-
ness of fit’ among the Spanish female population. A pre-
vious calibration test as an evaluation of the reliability
assessment of FRIDEX cohort results was carried out
using a lower number of women [25]. This analysis
suggests that the results are consistent with the above-
mentioned population. This study also provides informa-
tion on the frequency of risk factors of osteoporotic
fractures.
Risk factors of osteoporotic fracture
Age is a variable related to the incidence of fracture and
in our cohort the overall reported rates of fractures is
higher in the group over 65 years old (p < 0.001). When
focusing individually on hip, clinical spine, forearm and
humerus fractures, the proportion of fractures increases
with age. However, these differences were not statisti-
cally significant in the case of humerus fractures in our
sample. In addition to age, prior fragility fracture, low
BMI, rheumatoid arthritis or glucocorticoids intake are
clinical factors related to the pathogenesis of osteopor-
otic fracture, and indeed, the results of our study have
shown statistical significance in major fracture and hip
fracture. These results align well with other studies
undertaken in our population, which have identified the
same relevant factors for fragility fracture except for
BMI [30]. We also have found previously published data
that investigate relationship between BMI and fracture
in Spanish postmenopausal women, but focusing in high
BMI. In this context, some reported a relation between
vertebral fracture and high BMI [31] and, conversely,
other studies found no relation in this site, only for
proximal humerus fractures [32]. So further studies will
be needed to clarify these variations.
We also note that in evaluating Spanish FRAX tool esti-
mates without T-score, the risk of main fracture and hip
fracture obtained is significantly higher among women
with fractures than those without fractures. The contribu-
tion of BMD in the osteoporotic fracture risk is reflected
in the results of our sample as well, showing a lower aver-
age of BMD and increased FRAX estimates with FN T-
score between women with fracture compared to women
without fracture (p <0.05) (Tables 3 and 4).
Assessing FRAX-Spain discrimination performance
The ROC analysis used to assess the discriminatory cap-
acity of the FRAX osteoporotic fracture estimates, shows a
more accurate AUC of FRAX in major fractures with a
FN T-score [0.714, 95 % CI 0.661–0.767] and for hip frac-
ture with FRAX without BMD [0.883, 95 % CI 0.827–
0.938)]. These findings match those already reported in
the previous FRIDEX sample and are similar to those
found in other research conducted in Spain [25, 27].
The aforementioned finding bear out the current trend
for assessing fracture risk using clinical risk factors ra-
ther than only using the DXA results.
Regarding the older population with a higher susceptibil-
ity to fractures, especially in the case of hip fractures, these
results are particularly relevant as they enhance clinical
decision-making in practices that have a more limited ac-
cess to DXA. It is worth noting that results in other nearby
countries have shown a similar ability using FRAX with FN
T-score to identify women at a high risk of major fracture
compared to when the FN BMD is solely used [15, 19].
Assessing FRAX-Spain predictive performance
The adjusted predictive capacity of the FRAX tool ana-
lysed using the ObsFx/ExpFx ratio shows no correlation
Table 5 Ratio Observed fractures/Expected fractures by FRAX tool by age
Major fracturesa Hip fractures
All (1308 women) Obs Fx Exp Fx Ratio Obs/Exp CI 95 % Obs Fx Exp Fx Ratio Obs/Exp CI 95 %
FRAX tool without BMD 108 47.1 2.29 [1.9–2.4] 26 11.41 2.28 [1.6–3.3]
FRAX tool with T-score FN 108 53.6 2.01 [1.7–2.4] 26 14.20 1.83 [1.3–2.7]
<65 years (1056 women) Obs Fx Exp Fx Ratio Obs/Exp CI 95 % Obs Fx Exp Fx Ratio Obs/Exp CI 95 %
FRAX tool without BMD 65 27.2 2.39 [1.9–3.0] 6 3.91 1.53 [0.7–3.3]
FRAX tool with T-score FN 65 30.6 2.12 [1.7–2.7] 6 4.84 1.24 [0.6–2.7]
≥65 years (252 women) Obs Fx Exp Fx Ratio Obs/Exp CI 95 % Obs Fx Exp Fx Ratio Obs/Exp CI 95 %
FRAX tool without BMD 43 19.9 2.16 [1.6–2.8] 20 7.50 2.67 [1.7–4.0]
FRAX tool with T-score FN 43 23.0 1.87 [1.4–2.4] 20 9.36 2.14 [1.3–3.2]
ObsFx observed fractures, ExpFx expected fractures, CI confident interval, BMD bone mineral density, FN femoral neck
aMajor fractures (hip, vertebra, humerus, wrist)
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between observed and expected fracture rates among
Spanish population. All the women in the sample cohort
when analysed together showed a higher frequency of
fragility fracture (close 2 times more) than would be ex-
pected with FRAX tool either if it is calculated with the
FN T-score or without BMD (Table 5). This difference is
lower for hip fracture with FRAX with FN T-score of
DXA (ObsFx/ExpFx ratio all cohort 1.83) and clearly
better in women < 65 years old (Table 5). It could be ex-
plained by the mean age of the women in the study, with
80 % of the cohort being under the age of 65. Osteopor-
otic fracture that tends to occur in early menopause
Fig. 1 Hosmer-Lemeshow test with the original results of the FRAX tool
Azagra et al. BMC Musculoskeletal Disorders  (2016) 17:262 Page 7 of 10
affects the lumbar spine more than the hip, as hip BMD
decreases exponentially with advancing age [33–35]. As
observed in our study, when the ratio of observed to ex-
pected hip fracture is calculated for those aged 65 or
older with FRAX with FN T-score, the probability of hip
fracture increases two fold again.
The Hosmer-Lemeshow test was carried out to assess
the goodness of fit between observed fractures and the
expected fractures according to FRAX. A satisfactory
goodness of fit was obtained by multiplying the results
by the ObsFx/ExpFx ratio taking into account the CI
95 % (Fig. 1).
The Spanish FRAX model has been evaluated in other
cohorts. The ECOSAP cohort published similar hip frac-
ture risk prediction, but they did not collect clinical ver-
tebral fractures, therefore the interpretation of the
results for prediction of major osteoporotic fractures is
difficult [26]. In contrast, the methodology for collecting
incident fractures considered by FRAX in the CETIR
database was complete (clinical spine, hip, distal forearm
and proximal humerus) and self-reported with further
validation too [27]. In the results observed, the ObsFx/
ExpFx ratio for major fractures was 2.4 (CI 95 %: 2.1–
2.7) and 0.8 (CI 95 %: 0.6–1.1) for hip fractures. There-
fore, the major fracture results are in accordance with
our findings indicating that the FRAX model underesti-
mates fracture risk in Spanish women [25]. The possible
explanation for this underdiagnosed has already been
justified because for Spain, the data included in FRAX
are from studies conducted in the 90s [25–27], validated
in areas of a low incidence of hip fracture and more up-
to-date fracture incidence and mortality data is required
for fracture predictions [18, 36–38]. Therefore, some au-
thors have suggested that these methodological factors
may affect the interpretation of calibration, and should
be taken into account before making an assessment of
the tool [39–41]. The ratio for hip fracture in this case is
closer to 1, the desired value. One possible explanation
of this lack of accuracy may be due to the fact that, al-
though the initial formation of the two cohorts followed
very similar schemes, the other female Spanish cohorts
were younger [25, 27]. The differences among the three
Spanish cohorts’ findings can also be justified by the fact
that the ECOSAP and CETIR cohorts were comprised of
a low proportion of women over 70 years, a shorter aver-
age follow-up period, a low proportion of hip fractures
and a different method of follow up was used [26, 27].
Therefore, this could account for the differences in the hip
fracture ratio. The predicted probabilities of fragility frac-
ture using the Spanish FRAX tool have also been analysed
in FRODOS and ESOSVAL cohorts but the observed inci-
dence of osteoporotic fracture was not recorded. There-
fore, their data cannot be used to assess the predictive
ability of the tool [42, 43].
The study has some strengths and limitations. The
strengths of our study include among the 3397 poten-
tially eligible subjects contacted for the study, there were
no significant differences in most of the basic character-
istics between participants and non-participants. The
differences found in mean age, prior fracture, corticoste-
roids use and osteoporosis BMD result were very small,
thus we assume that the sample was representative from
the population from which it was taken. To determine
incident osteoporotic fractures some countries, in the
first place, review hospital hip fracture discharge statis-
tics assuming that all proximal femoral fractures result
in hospitalization. In the case of the remaining major
fractures (humerus, clinical spine, forearm) others stud-
ies used incidence fracture data taken from a cohort in
Malmö, working on the premise that the ratios would be
similar [44–48]. In the present study, all fractures re-
corded via the use of a telephone questionnaire were
contrasted with existing medical record data and only
included in the final analysis if the fractures were also
found both in the medical records and via the telephone
questionnaire. There are also limitations. Working on
the assumption that the women included in the FRIDEX
cohort could have a higher risk of osteoporotic fractures
than the general population due to the fact that it is a
population that had previously been selected to undergo
a DXA scan for different reasons. Currently, there is evi-
dence that the women included in the FRIDEX cohort
have not a higher incidence of fragility fracture than the
general population, although they have more risk factors
for fragility fracture [7, 25, 49]. In the present analysis,
deceased patients were excluded and this should be
taken into consideration. Despite the fact the number of
deceased patients only made up 5.8 % of the cohort, it
could lead to a misinterpretation of observed fractures
[50]. Finally, our data has been confined to women and
we still do not know if a similar result would be ob-
tained in men, further studies would be necessary to as-
certain this.
Conclusions
In summary, based on the study’s finding, the FRAX tool
has been found to show a good discriminatory capacity
for detecting women at high risk of fragility fracture. In
the case of hip fractures, this discriminatory capacity of
the FRAX tool without BMD was found to be higher
than when using BMD alone. Possibly, further studies in
Catalonia and other regions of Spain would be required
to fine tune the FRAX tool’s predictive capability.
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